"HSR24-133: Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) After Luspatercept in Patients (pts) With Myelodysplastic Syndromes (MDS): A Retrospective Analysis of a Large Healthcare Claims Database in the United States" published on 05 Apr 2024 by National Comprehensive Cancer Network.
No takes yet. Share an insight, caveat, or question.
Hanna et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: